Product Images Fluticasone Propionate And Salmeterol Diskus
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 18 images provide visual information about the product associated with Fluticasone Propionate And Salmeterol Diskus NDC 66993-584 by Prasco Laboratories, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
fluticasone propionate chemical structure - fp sal spl graphic 01
salmeterol xinafoate chemical structure - fp sal spl graphic 02
Figure 1. Mean Percent Change From Baseline in FEV1 in Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 03
This appears to be a graph showing the change in forced expiratory volume (FEV) over 12 weeks for three treatments: fluticasone propionate/salmeterol 100/50mg twice daily, fluticasone propionate 100mg twice daily plus salmeterol 50mg twice daily, and placebo. The graph shows that both of the fluticasone/salmeterol treatments resulted in increased FEV over the 12 weeks, while the placebo treatment did not. The endpoint for the fluticasone propionate/salmeterol treatment was around 87, compared to around 85 for the other two treatments.*
Figure 2. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 04
This is a graph showing the percent change in FEV4 (Forced Expiratory Volume in 4 seconds) over time for four different treatments: Fluticasone propionate/salmeterol 100/50 µg twice daily (N = 87), Salmeterol 50 µg twice daily (N = 86), Fluticasone propionate 100 µg twice daily (N = 85), and Placebo (N=77). The x-axis represents the days of the study, and the y-axis represents the percentage change in FEV4. However, there is no information on the study's objective or duration, and no conclusions can be drawn based on this graph alone.*
Figure 3. Percent Change in Serial 12-hour FEV1 in Subjects With Asthma Previously Using Either Inhaled Corticosteroids or Salmeterol (Trial 1) - fp sal spl graphic 05
This appears to be a graph showing the change in Forced Expiratory Volume (FEV) over time for different treatment groups. The treatments include Fluticasone propionate/salmeterol, Salmeterol, Fluticasone propionate, and a Placebo, with each group having a different number of participants (N). The x-axis shows the time up to 12 weeks, and the y-axis shows the percentage change in FEV relative to the Day 1 Baseline measurement. The graph seems to indicate that the group treated with Fluticasone propionate/salmeterol had the largest improvement in FEV compared to the other treatment groups.*
Figure 4. Predose FEV1: Mean Percent Change From Baseline in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 06
This text appears to be reporting results from a medical study comparing the effectiveness of three different treatments for a respiratory condition, including a combination of fluticasone propionate and salmeterol, salmeterol alone, and a placebo. The text includes graphs tracking the participants' lung function over the course of the study (measured in mL). However, the specific results are not clear without further context or interpretation.*
Figure 5. Two-Hour Postdose FEV1: Mean Percent Changes From Baseline Over Time in Subjects With Chronic Obstructive Pulmonary Disease - fp sal spl graphic 07
This text appears to be a clinical study report on the use of Fluticasone Propionate and Salmeterol inhalers for COPD patients. It details the dosages given and the results of the study as determined by baseline FEV1 measurements. The text includes a graph showing the results at various endpoints.*
Figure A - fp sal spl graphic 08
Putiasone and Salmeterol DISKUS is an inhaler powder used for treating asthma and chronic obstructive pulmonary disease (COPD). The inhaler comes with a mouthpiece and lever. The rest of the text is not available.*
Figure B - fp sal spl graphic 09
Figure C - fp sal spl graphic 10
IFU Figure D - fp sal spl graphic 11
Figure E - fp sal spl graphic 12
Figure F - fp sal spl graphic 13
IFU Figure G - fp sal spl graphic 14
Figure H - fp sal spl graphic 15
Fluticasone Propionate-Salmeterol Diskus 100-50 mcg carton - fp sal spl graphic 16
This is a product description for a prescription medication with the NDC number 66993-584-97. The medication is called Fluticasone Propionate/Salmeterol DISKUS Inhalation Powder and is only for oral inhalation. Each blister contains 100 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate (equivalent to 50mcg of salmeterol base) with lactose. It also includes a DISKUS Inhalation Device which contains one foil strip of 60 blisters.*
Fluticasone Propionate-Salmeterol Diskus 250-50 mcg carton - fp sal spl graphic 17
This is a prescription drug called "Fluticasone Propionate/Salmeterol DISKUS Inhalation Powder" by Prasco. It comes as a device that contains 60 blisters, each blister has 250 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate. It is meant to be taken orally by inhalation and each blister has lactose.*
Fluticasone Propionate-Salmeterol Diskus 500-50 mcg carton - fp sal spl graphic 18
This is a prescription drug with NDC code 66993-586-97. It is a combination of Fluticasone Propionate and Salmeterol in a Diskus inhalation powder form that contains 500 mcg/50 mcgq. It is used for oral inhalation only and each blister contains 500 mcg of fluticasone propionate and 72.5 mcg of salmeterol xinafoate, equivalent to 50 mcg of salmeterol base. The drug comes with one Diskus inhalation device containing one foil strip of 60 blisters.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.